Navigation Links
ThromboGenics N.V.: Business Update

LEUVEN, Belgium, November 6 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update for the nine months period ended 30 September 2008.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics' clinical development programs continue to progress as anticipated. We are now working hard to prepare for the Phase III clinical program for microplasmin in eye disease following a successful End of Phase II Meeting with the FDA. The recent positive results from our Phase II trials with microplasmin have given us further confidence that this product has the potential to make a real difference in the field of eye disease. We are also developing a good working relationship with our strategic partner Roche as the clinical development of our new anti-cancer antibody TB-403 continues to progress. With our solid financial situation, I believe that ThromboGenics will deliver further important corporate milestones over the next 12 to 18 months as we continue to work to build value for our shareholders."
Financial Update

- In the first nine months of 2008, ThromboGenics achieved

revenues of EUR 30.3 million, mainly from out-licensing activities.

Operating expenses were EUR 17.0 million during this nine month period,

the majority of which were due to R&D expenses related to an increasing

number of clinical development programs.

- As of 30 September 2008, ThromboGenics had EUR 60.9 million

in cash and cash equivalents. This compares to EUR 50.6 million on 30

September 2007 and EUR 40.1 million on 31 December 2007. ThromboGenics

believes that this level of funding will allow it to complete the Phase

III program for the initial indication for microplasmin in eye disease.

- In late July, ThromboG

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
(Date:10/9/2015)... PHILADELPHIA , Oct. 9, 2015 Governor ... a clinical stage biopharmaceutical company focused on developing T-cell ... new, high-paying jobs with a new expansion project. ... great news for the commonwealth as 110 new, high-paying ... Tom Wolf . "My budget proposal includes sustained ...
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... Leading ... study that aims to better understand the relationship between weight management and the microbiome. ... and more accurately from participants using an iPhone app. , The uBiome app is ...
(Date:10/8/2015)... , Oct. 8, 2015  ATCC, the premier global ... it has been selected by The Michael J. Fox ... lines to academic, pharmaceutical, and biotechnology organizations committed to ... the United States , and more than ... the United States , and more than ...
(Date:10/8/2015)... Texas , Oct. 8, 2015 The 2015 ... of The University of Texas at Dallas. Aziz Sancar ... UT Dallas in 1977, is one of ... how cells continuously monitor and repair damaged DNA on a molecular ... in molecular and cell biology from UT Dallas ...
Breaking Biology Technology:
... 21 ViroPharma Incorporated,s (Nasdaq: VPHM ) second quarter financial results for ... the open of the U.S. financial markets. , ... company will host a conference call and live audio webcast at 9:00 a.m. ... discuss the 2010 second quarter financial results and other business. , ...
... Keck Graduate Institute (KGI) Director of Research Angelika Niemz has been ... of Health (NIH). , , , ... focus on developing assays and devices to diagnose multi-drug resistant tuberculosis at the point ... , , ...
... and CAMBRIDGE, MA , July 21 /PRNewswire-FirstCall/ ... drug candidates, high-value proteins and oils utilizing its novel plant ... joined the Company as President of US and International Operations. ... Massachusetts which will offer the Company a broader market ...
Cached Biology Technology:
(Date:9/9/2015)... , Sept. 9, 2015  NuData Security announced ... solution-based milestones, furthering the company,s commitment to protecting ... fraud. NuData Security,s online fraud detection ... company,s growth cycle. The product combines continual analysis ... good user behavior from fraudulent behavior, allowing the ...
(Date:9/2/2015)... 2, 2015 About hand geometry biometrics ... government organizations, telecommunication and hospitals as well as for ... and numeric keypads are used to prevent unauthorised access. ... and fingers of an individual, width of the fingers, ... infrared light and reflectors can be used for capturing ...
(Date:9/1/2015)... 2015  Automation and pre-processing are reducing the ... This is the first step toward a future ... unintrusive. An assortment of portal scanners, biometric collection ... will transform the passenger screening process. ... Airport Passenger Screening Market ( ), ...
Breaking Biology News(10 mins):
... are documenting the growing effects of climate change, carbon dioxide, ... most of those have studied single, isolated sources of pollution ... Woods Hole Oceanographic Institution (WHOI) has published a report in ... evaluates the total impact of such factors on the ocean ...
... Cold sensing neural circuits in newborn mice take around two ... The finding adds to understanding of the cold sensing ... paper in 2002 by David McKemy of the University ... Neuroscience, shows that the cold sensing circuit starts to develop ...
... sets of factors can reprogram human cells to induced ... cells are not easily accessible to minimally invasive procedures. ... Associations for Dental Research,s Journal of Dental Research ... H. Aoki, T. Takeda-Kawaguchi, K. Iida, T. Kunisada and ...
Cached Biology News:
... vectors are designed for enhanced translation of cloned ... rabbit reticulocyte lysate. The maps for pCITE-2b(+) and ... following exceptions: pCITE-2b(+) is a 3793 bp plasmid; ... and Xcm I sites. Subtract 7 bp from ...
Biology Products: